AND EXCHANGE COMMISSION
TO SECTION 13 OR 15(d) OF THE
EXCHANGE ACT OF 1934
of report (Date of earliest event reported): January 25, 2018
Name of Registrant as Specified in Charter)
or Other Jurisdiction
Recreation Park Drive, Unit 108
of Principal Executive Offices) (Zip Code)
telephone number, including area code: (781) 875-3605
Name or Former Address, if Changed Since Last Report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [ ]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
3.02. Unregistered Sales of Equity Securities.
November 22, 2017 through January 25, 2018, the holder of the Series A Convertible Preferred Stock, par value $0.01 per share
(the “Preferred Stock”), of Microbot Medical Inc. (the “Registrant”), converted an aggregate of 2,436
shares of the Preferred Stock for an aggregate of 2,436,000 shares of the Registrant’s common stock. Pursuant to the terms
of conversion of the Preferred Stock, each such share is convertible, upon request and for no additional consideration, into 1,000
shares of the common stock of the Registrant. The issuances of the 2,436,000 shares of common stock were exempt from registration
under Section 4(a)(2) under the Securities Act of 1933, as amended and the rules promulgated thereunder (the “Securities
Act”) as transactions not involving a public offering to a single existing stockholder who is an accredited investor, and/or
3(a)(9) under the Securities Act as the Preferred Stock was exchanged for common stock by an existing security holder and no commission
or other remuneration was paid.
December 11, 2017, the Registrant issued an aggregate of 70,000 shares of the Registrant’s common stock to a consultant
as consideration for services. The issuance of the shares was exempt from registration under Section 4(a)(2) under the Securities
Act as a transaction not involving a public offering, as the issuance thereof was made to a limited number of persons or entities
as compensation for services rendered.
7.01 Regulation FD Disclosure
January 31, 2018, the Registrant issued a press release announcing that it will host regularly scheduled Townhall Meetings to
allow shareholders and interested investors to get updates and participate in a Q&A session with senior executives of the
Company. The initial Townhall Meeting is scheduled for Thursday, February 1, 2018 at 4:30pm ET.
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including
9.01 Financial Statements and Exhibits
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
||MICROBOT MEDICAL INC.|
President and |
Chief Executive Officer
January 31, 2018